Stigma Affects 20 Percent of HIV Vaccine Trial Participants
HIV vaccine researchers need to place more emphasis on protecting vaccine trial participants’ privacy and reducing the negative social consequences to them. Stigma affects nearly 20 percent of trial participants, suggests a report in the November issue of Journal of Acquired Immune Deficiency Syndromes (aidsmap.com, 11/15).
In a study of 5,417 trial participants, 18 percent reported that they’d experienced some range of negative social impacts such as unintentional disclosure or problems with housing, medical care, relationships, employment, insurance or travel.
The most common social impact reported was negative reactions from friends, family members and partners that the vaccine could infect participants.
whnormanjr
